Potential interactions between traditional Chinese medicine and osimertinib: a Case Report
Osimertinib, a third-generation EGFR tyrosine kinase inhibitor, played a crucial role in the treatment of EGFR-mutated non-small cell lung cancer. This case firstly reported a case of drug-drug interaction between traditional Chinese medicine (TCM) and osimertinib. A 57-year-old female was diagnosed...
Saved in:
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2025-06-01
|
| Series: | Frontiers in Pharmacology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fphar.2025.1596913/full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|